TipRanks
Advertisement
Advertisement

BIOA Stock Latest News

BioAge Labs initiates Phase 2 trial for BGE-102
Company AnnouncementsBioAge Labs initiates Phase 2 trial for BGE-102
38s ago
8K
BIOA
BioAge Therapeutics: Buy Rating Reiterated with Compelling 198% Upside and Maintained $21 Price Target on Inflammation-Targeted Retinal Therapy Validation
PremiumRatings
BioAge Therapeutics: Buy Rating Reiterated with Compelling 198% Upside and Maintained $21 Price Target on Inflammation-Targeted Retinal Therapy Validation
3d ago
BIOA
BioAge Labs doses first patient in QUELL-DME study
PremiumThe Fly
BioAge Labs doses first patient in QUELL-DME study
24d ago
BIOA
3 Stocks Under $10 With Over 100% Upside, According to Analysts
PremiumMarket News
3 Stocks Under $10 With Over 100% Upside, According to Analysts
1M ago
LLY
NVS
BioAge Labs price target lowered to $20 from $23 at Morgan Stanley
PremiumThe Fly
BioAge Labs price target lowered to $20 from $23 at Morgan Stanley
2M ago
BIOA
BioAge Labs: Upstream NLRP3 Strategy and Strong Cash Runway Underpin Unchanged $35 Price Target and Buy Rating
PremiumRatingsBioAge Labs: Upstream NLRP3 Strategy and Strong Cash Runway Underpin Unchanged $35 Price Target and Buy Rating
2M ago
BIOA
BioAge Labs price target lowered to $21 from $52 at Citi
Premium
The Fly
BioAge Labs price target lowered to $21 from $52 at Citi
2M ago
BIOA
Andy Hsieh Reiterates Hold on BioAge as Strong Cash Runway Offsets Execution and Clinical Surrogate Uncertainties
Premium
Ratings
Andy Hsieh Reiterates Hold on BioAge as Strong Cash Runway Offsets Execution and Clinical Surrogate Uncertainties
2M ago
BIOA
BioAge Labs reports Q2 EPS (58c), consensus (62c)
PremiumThe Fly
BioAge Labs reports Q2 EPS (58c), consensus (62c)
2M ago
BIOA
Shrader Reiterates Buy on BioAge, Citing Differentiated NLRP3 Strategy and Attractive Valuation with Unchanged $40 Price Target
PremiumRatings
Shrader Reiterates Buy on BioAge, Citing Differentiated NLRP3 Strategy and Attractive Valuation with Unchanged $40 Price Target
2M ago
BIOA
Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback
PremiumThe Fly
Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback
2M ago
NVO
BIOA
BioAge Labs price target lowered to $25 from $36 at Roth Capital
PremiumThe Fly
BioAge Labs price target lowered to $25 from $36 at Roth Capital
2M ago
NVO
BIOA
BioAge Therapeutics: Buy Rating Maintained Despite Cut in Price Target to $21 on Refined ASCVD and Ocular Program Assumptions
PremiumRatingsBioAge Therapeutics: Buy Rating Maintained Despite Cut in Price Target to $21 on Refined ASCVD and Ocular Program Assumptions
2M ago
BIOA
Buy Rating Reaffirmed on BioAge: Sell-Off Seen as Overdone Amid Validated NLRP3 Platform and Triple-Digit Upside Potential
Premium
Ratings
Buy Rating Reaffirmed on BioAge: Sell-Off Seen as Overdone Amid Validated NLRP3 Platform and Triple-Digit Upside Potential
2M ago
BIOA
BioAge Labs pullback after ZEUS data ‘seems overdone,’ says Citi
Premium
The Fly
BioAge Labs pullback after ZEUS data ‘seems overdone,’ says Citi
2M ago
NVO
BIOA
BioAge Labs price target lowered at Jefferies after Novo trial miss
PremiumThe Fly
BioAge Labs price target lowered at Jefferies after Novo trial miss
2M ago
NVO
BIOA
BioAge Labs price target lowered to $50 from $60 at Oppenheimer
PremiumThe Fly
BioAge Labs price target lowered to $50 from $60 at Oppenheimer
2M ago
BIOA
BioAge Labs: Buy Rating Reiterated on NLRP3 Pathway Validation Potential; $50 Price Target Maintained
PremiumRatings
BioAge Labs: Buy Rating Reiterated on NLRP3 Pathway Validation Potential; $50 Price Target Maintained
3M ago
BIOA
BioAge Moves BGE-102 Into Mid-Stage Obesity Heart-Risk Trial, Raising New Investor Focus
PremiumCompany Announcements
BioAge Moves BGE-102 Into Mid-Stage Obesity Heart-Risk Trial, Raising New Investor Focus
4M ago
BIOA
BioAge Labs doses first participant in QUELL-CV trial of BGE-102
PremiumThe FlyBioAge Labs doses first participant in QUELL-CV trial of BGE-102
4M ago
BIOA
BioAge Labs Shareholders Reelect Directors, Ratify Auditor
Premium
Company Announcements
BioAge Labs Shareholders Reelect Directors, Ratify Auditor
4M ago
8K
BIOA
BioAge Labs initiated with a Buy at Roth Capital
Premium
The Fly
BioAge Labs initiated with a Buy at Roth Capital
4M ago
BIOA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >